BIOMED PHARMACOTHER 润色咨询

BIOMEDICINE & PHARMACOTHERAPY

出版年份:1982 年文章数:8228 投稿命中率: 开通期刊会员,数据随心看

出版周期:Bimonthly 自引率:10.8% 审稿周期: 开通期刊会员,数据随心看

前往期刊查询

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=2185142, encodeId=63162185142c0, content=多久有人愿意审稿呀。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22b46401167, createdName=ms8000001441772842, createdTime=Wed Jan 31 23:23:06 CST 2024, time=2024-01-31, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2189500, encodeId=7ef62189500b2, content=偏重的研究方向:肿瘤<br>经验分享:年前投稿的,昨天送审,1000+号, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4019047506, createdName=ms2000001254072347, createdTime=Mon Feb 26 19:11:05 CST 2024, time=2024-02-26, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2192087, encodeId=2e7d219208ead, content=记录一下,2.16投稿的,1300+,今天还是Submitted to journal, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=aa0b5490731, createdName=chy, createdTime=Fri Mar 08 14:54:38 CST 2024, time=2024-03-08, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2175017, encodeId=05c721e5017e2, content=审稿速度:1.0 | 投稿命中率:75.0<br>偏重的研究方向:肿瘤;综述<br>经验分享:66**号,第二次投稿(8月初第一次没找到审稿人,一个月拒了,说欢迎修改题目和关键词后重投),第二次投稿邀请了25个人,终于找到了一个审稿人愿意审稿,小修了2次(相当于这个审稿人审了3次文章),每次都是审10天左右,然后等编辑5天左右做决定,也就是一次修稿周期就得20天,今天终于接收了。9月18号投的稿。 送审之后修回的概率很大,对大而不精的综述特别友好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/20/36e4b1345247d92b63b923885e50e463.jpg, createdBy=921d5250503, createdName=147ddcd3m55暂无昵称, createdTime=Fri Dec 15 01:05:53 CST 2023, time=2023-12-15, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2192558, encodeId=95eb21925583c, content=记录一下,2月22日投稿,1600+,还是submitted to journal, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2f7f5535320, createdName=ms3000000361924578, createdTime=Mon Mar 11 14:09:31 CST 2024, time=2024-03-11, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2185510, encodeId=c458218551089, content=偏重的研究方向:心血管<br>经验分享:2023年12月8 Submitted<br>2024年1月15 with editor<br>2024年1月30 Under Review<br>还要多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=98188622439, createdName=ms3000001775227501, createdTime=Fri Feb 02 15:09:20 CST 2024, time=2024-02-02, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2193046, encodeId=494b21930461d, content=偏重的研究方向:肿瘤;综述<br>经验分享:为啥找不到审稿人呢<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4019047506, createdName=ms2000001254072347, createdTime=Wed Mar 13 20:37:05 CST 2024, time=2024-03-13, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2194188, encodeId=3695219418871, content=好像最近没有中国人的论著文章发表, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0ea8286723, createdName=ms3000000851999119, createdTime=Tue Mar 19 23:26:22 CST 2024, time=2024-03-19, status=1, ipAttribution=弗吉尼亚), GetPortalCommentsPageByObjectIdResponse(id=2193430, encodeId=d7612193430bc, content=在线求BIOMED PHARMACOTHER 官网邮箱,谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2e651733589, createdName=今夜有雨, createdTime=Fri Mar 15 16:36:23 CST 2024, time=2024-03-15, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2189719, encodeId=4dde2189e1973, content=写邮件申请延长修稿时间是直接回复系统发送的邮件还是在官网系统上发送邮件啊?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18898386622, createdName=ms7000000856963905, createdTime=Tue Feb 27 18:39:38 CST 2024, time=2024-02-27, status=1, ipAttribution=江苏省)]
    2024-01-31 ms8000001441772842 来自北京

    多久有人愿意审稿呀。

    4

    展开4条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=2185142, encodeId=63162185142c0, content=多久有人愿意审稿呀。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22b46401167, createdName=ms8000001441772842, createdTime=Wed Jan 31 23:23:06 CST 2024, time=2024-01-31, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2189500, encodeId=7ef62189500b2, content=偏重的研究方向:肿瘤<br>经验分享:年前投稿的,昨天送审,1000+号, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4019047506, createdName=ms2000001254072347, createdTime=Mon Feb 26 19:11:05 CST 2024, time=2024-02-26, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2192087, encodeId=2e7d219208ead, content=记录一下,2.16投稿的,1300+,今天还是Submitted to journal, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=aa0b5490731, createdName=chy, createdTime=Fri Mar 08 14:54:38 CST 2024, time=2024-03-08, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2175017, encodeId=05c721e5017e2, content=审稿速度:1.0 | 投稿命中率:75.0<br>偏重的研究方向:肿瘤;综述<br>经验分享:66**号,第二次投稿(8月初第一次没找到审稿人,一个月拒了,说欢迎修改题目和关键词后重投),第二次投稿邀请了25个人,终于找到了一个审稿人愿意审稿,小修了2次(相当于这个审稿人审了3次文章),每次都是审10天左右,然后等编辑5天左右做决定,也就是一次修稿周期就得20天,今天终于接收了。9月18号投的稿。 送审之后修回的概率很大,对大而不精的综述特别友好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/20/36e4b1345247d92b63b923885e50e463.jpg, createdBy=921d5250503, createdName=147ddcd3m55暂无昵称, createdTime=Fri Dec 15 01:05:53 CST 2023, time=2023-12-15, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2192558, encodeId=95eb21925583c, content=记录一下,2月22日投稿,1600+,还是submitted to journal, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2f7f5535320, createdName=ms3000000361924578, createdTime=Mon Mar 11 14:09:31 CST 2024, time=2024-03-11, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2185510, encodeId=c458218551089, content=偏重的研究方向:心血管<br>经验分享:2023年12月8 Submitted<br>2024年1月15 with editor<br>2024年1月30 Under Review<br>还要多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=98188622439, createdName=ms3000001775227501, createdTime=Fri Feb 02 15:09:20 CST 2024, time=2024-02-02, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2193046, encodeId=494b21930461d, content=偏重的研究方向:肿瘤;综述<br>经验分享:为啥找不到审稿人呢<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4019047506, createdName=ms2000001254072347, createdTime=Wed Mar 13 20:37:05 CST 2024, time=2024-03-13, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2194188, encodeId=3695219418871, content=好像最近没有中国人的论著文章发表, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0ea8286723, createdName=ms3000000851999119, createdTime=Tue Mar 19 23:26:22 CST 2024, time=2024-03-19, status=1, ipAttribution=弗吉尼亚), GetPortalCommentsPageByObjectIdResponse(id=2193430, encodeId=d7612193430bc, content=在线求BIOMED PHARMACOTHER 官网邮箱,谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2e651733589, createdName=今夜有雨, createdTime=Fri Mar 15 16:36:23 CST 2024, time=2024-03-15, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2189719, encodeId=4dde2189e1973, content=写邮件申请延长修稿时间是直接回复系统发送的邮件还是在官网系统上发送邮件啊?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18898386622, createdName=ms7000000856963905, createdTime=Tue Feb 27 18:39:38 CST 2024, time=2024-02-27, status=1, ipAttribution=江苏省)]
    2024-02-26 ms2000001254072347 来自四川省

    偏重的研究方向:肿瘤
    经验分享:年前投稿的,昨天送审,1000+号

    14

    展开14条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=2185142, encodeId=63162185142c0, content=多久有人愿意审稿呀。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22b46401167, createdName=ms8000001441772842, createdTime=Wed Jan 31 23:23:06 CST 2024, time=2024-01-31, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2189500, encodeId=7ef62189500b2, content=偏重的研究方向:肿瘤<br>经验分享:年前投稿的,昨天送审,1000+号, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4019047506, createdName=ms2000001254072347, createdTime=Mon Feb 26 19:11:05 CST 2024, time=2024-02-26, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2192087, encodeId=2e7d219208ead, content=记录一下,2.16投稿的,1300+,今天还是Submitted to journal, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=aa0b5490731, createdName=chy, createdTime=Fri Mar 08 14:54:38 CST 2024, time=2024-03-08, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2175017, encodeId=05c721e5017e2, content=审稿速度:1.0 | 投稿命中率:75.0<br>偏重的研究方向:肿瘤;综述<br>经验分享:66**号,第二次投稿(8月初第一次没找到审稿人,一个月拒了,说欢迎修改题目和关键词后重投),第二次投稿邀请了25个人,终于找到了一个审稿人愿意审稿,小修了2次(相当于这个审稿人审了3次文章),每次都是审10天左右,然后等编辑5天左右做决定,也就是一次修稿周期就得20天,今天终于接收了。9月18号投的稿。 送审之后修回的概率很大,对大而不精的综述特别友好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/20/36e4b1345247d92b63b923885e50e463.jpg, createdBy=921d5250503, createdName=147ddcd3m55暂无昵称, createdTime=Fri Dec 15 01:05:53 CST 2023, time=2023-12-15, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2192558, encodeId=95eb21925583c, content=记录一下,2月22日投稿,1600+,还是submitted to journal, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2f7f5535320, createdName=ms3000000361924578, createdTime=Mon Mar 11 14:09:31 CST 2024, time=2024-03-11, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2185510, encodeId=c458218551089, content=偏重的研究方向:心血管<br>经验分享:2023年12月8 Submitted<br>2024年1月15 with editor<br>2024年1月30 Under Review<br>还要多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=98188622439, createdName=ms3000001775227501, createdTime=Fri Feb 02 15:09:20 CST 2024, time=2024-02-02, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2193046, encodeId=494b21930461d, content=偏重的研究方向:肿瘤;综述<br>经验分享:为啥找不到审稿人呢<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4019047506, createdName=ms2000001254072347, createdTime=Wed Mar 13 20:37:05 CST 2024, time=2024-03-13, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2194188, encodeId=3695219418871, content=好像最近没有中国人的论著文章发表, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0ea8286723, createdName=ms3000000851999119, createdTime=Tue Mar 19 23:26:22 CST 2024, time=2024-03-19, status=1, ipAttribution=弗吉尼亚), GetPortalCommentsPageByObjectIdResponse(id=2193430, encodeId=d7612193430bc, content=在线求BIOMED PHARMACOTHER 官网邮箱,谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2e651733589, createdName=今夜有雨, createdTime=Fri Mar 15 16:36:23 CST 2024, time=2024-03-15, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2189719, encodeId=4dde2189e1973, content=写邮件申请延长修稿时间是直接回复系统发送的邮件还是在官网系统上发送邮件啊?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18898386622, createdName=ms7000000856963905, createdTime=Tue Feb 27 18:39:38 CST 2024, time=2024-02-27, status=1, ipAttribution=江苏省)]
    2024-03-08 chy 来自辽宁省

    记录一下,2.16投稿的,1300+,今天还是Submitted to journal

    10

    展开10条回复
  4. [GetPortalCommentsPageByObjectIdResponse(id=2185142, encodeId=63162185142c0, content=多久有人愿意审稿呀。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22b46401167, createdName=ms8000001441772842, createdTime=Wed Jan 31 23:23:06 CST 2024, time=2024-01-31, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2189500, encodeId=7ef62189500b2, content=偏重的研究方向:肿瘤<br>经验分享:年前投稿的,昨天送审,1000+号, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4019047506, createdName=ms2000001254072347, createdTime=Mon Feb 26 19:11:05 CST 2024, time=2024-02-26, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2192087, encodeId=2e7d219208ead, content=记录一下,2.16投稿的,1300+,今天还是Submitted to journal, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=aa0b5490731, createdName=chy, createdTime=Fri Mar 08 14:54:38 CST 2024, time=2024-03-08, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2175017, encodeId=05c721e5017e2, content=审稿速度:1.0 | 投稿命中率:75.0<br>偏重的研究方向:肿瘤;综述<br>经验分享:66**号,第二次投稿(8月初第一次没找到审稿人,一个月拒了,说欢迎修改题目和关键词后重投),第二次投稿邀请了25个人,终于找到了一个审稿人愿意审稿,小修了2次(相当于这个审稿人审了3次文章),每次都是审10天左右,然后等编辑5天左右做决定,也就是一次修稿周期就得20天,今天终于接收了。9月18号投的稿。 送审之后修回的概率很大,对大而不精的综述特别友好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/20/36e4b1345247d92b63b923885e50e463.jpg, createdBy=921d5250503, createdName=147ddcd3m55暂无昵称, createdTime=Fri Dec 15 01:05:53 CST 2023, time=2023-12-15, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2192558, encodeId=95eb21925583c, content=记录一下,2月22日投稿,1600+,还是submitted to journal, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2f7f5535320, createdName=ms3000000361924578, createdTime=Mon Mar 11 14:09:31 CST 2024, time=2024-03-11, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2185510, encodeId=c458218551089, content=偏重的研究方向:心血管<br>经验分享:2023年12月8 Submitted<br>2024年1月15 with editor<br>2024年1月30 Under Review<br>还要多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=98188622439, createdName=ms3000001775227501, createdTime=Fri Feb 02 15:09:20 CST 2024, time=2024-02-02, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2193046, encodeId=494b21930461d, content=偏重的研究方向:肿瘤;综述<br>经验分享:为啥找不到审稿人呢<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4019047506, createdName=ms2000001254072347, createdTime=Wed Mar 13 20:37:05 CST 2024, time=2024-03-13, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2194188, encodeId=3695219418871, content=好像最近没有中国人的论著文章发表, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0ea8286723, createdName=ms3000000851999119, createdTime=Tue Mar 19 23:26:22 CST 2024, time=2024-03-19, status=1, ipAttribution=弗吉尼亚), GetPortalCommentsPageByObjectIdResponse(id=2193430, encodeId=d7612193430bc, content=在线求BIOMED PHARMACOTHER 官网邮箱,谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2e651733589, createdName=今夜有雨, createdTime=Fri Mar 15 16:36:23 CST 2024, time=2024-03-15, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2189719, encodeId=4dde2189e1973, content=写邮件申请延长修稿时间是直接回复系统发送的邮件还是在官网系统上发送邮件啊?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18898386622, createdName=ms7000000856963905, createdTime=Tue Feb 27 18:39:38 CST 2024, time=2024-02-27, status=1, ipAttribution=江苏省)]
    2023-12-15 147ddcd3m55暂无昵称 来自北京

    审稿速度:1.0 | 投稿命中率:75.0
    偏重的研究方向:肿瘤;综述
    经验分享:66**号,第二次投稿(8月初第一次没找到审稿人,一个月拒了,说欢迎修改题目和关键词后重投),第二次投稿邀请了25个人,终于找到了一个审稿人愿意审稿,小修了2次(相当于这个审稿人审了3次文章),每次都是审10天左右,然后等编辑5天左右做决定,也就是一次修稿周期就得20天,今天终于接收了。9月18号投的稿。 送审之后修回的概率很大,对大而不精的综述特别友好。

    8

    展开8条回复
  5. [GetPortalCommentsPageByObjectIdResponse(id=2185142, encodeId=63162185142c0, content=多久有人愿意审稿呀。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22b46401167, createdName=ms8000001441772842, createdTime=Wed Jan 31 23:23:06 CST 2024, time=2024-01-31, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2189500, encodeId=7ef62189500b2, content=偏重的研究方向:肿瘤<br>经验分享:年前投稿的,昨天送审,1000+号, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4019047506, createdName=ms2000001254072347, createdTime=Mon Feb 26 19:11:05 CST 2024, time=2024-02-26, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2192087, encodeId=2e7d219208ead, content=记录一下,2.16投稿的,1300+,今天还是Submitted to journal, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=aa0b5490731, createdName=chy, createdTime=Fri Mar 08 14:54:38 CST 2024, time=2024-03-08, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2175017, encodeId=05c721e5017e2, content=审稿速度:1.0 | 投稿命中率:75.0<br>偏重的研究方向:肿瘤;综述<br>经验分享:66**号,第二次投稿(8月初第一次没找到审稿人,一个月拒了,说欢迎修改题目和关键词后重投),第二次投稿邀请了25个人,终于找到了一个审稿人愿意审稿,小修了2次(相当于这个审稿人审了3次文章),每次都是审10天左右,然后等编辑5天左右做决定,也就是一次修稿周期就得20天,今天终于接收了。9月18号投的稿。 送审之后修回的概率很大,对大而不精的综述特别友好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/20/36e4b1345247d92b63b923885e50e463.jpg, createdBy=921d5250503, createdName=147ddcd3m55暂无昵称, createdTime=Fri Dec 15 01:05:53 CST 2023, time=2023-12-15, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2192558, encodeId=95eb21925583c, content=记录一下,2月22日投稿,1600+,还是submitted to journal, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2f7f5535320, createdName=ms3000000361924578, createdTime=Mon Mar 11 14:09:31 CST 2024, time=2024-03-11, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2185510, encodeId=c458218551089, content=偏重的研究方向:心血管<br>经验分享:2023年12月8 Submitted<br>2024年1月15 with editor<br>2024年1月30 Under Review<br>还要多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=98188622439, createdName=ms3000001775227501, createdTime=Fri Feb 02 15:09:20 CST 2024, time=2024-02-02, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2193046, encodeId=494b21930461d, content=偏重的研究方向:肿瘤;综述<br>经验分享:为啥找不到审稿人呢<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4019047506, createdName=ms2000001254072347, createdTime=Wed Mar 13 20:37:05 CST 2024, time=2024-03-13, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2194188, encodeId=3695219418871, content=好像最近没有中国人的论著文章发表, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0ea8286723, createdName=ms3000000851999119, createdTime=Tue Mar 19 23:26:22 CST 2024, time=2024-03-19, status=1, ipAttribution=弗吉尼亚), GetPortalCommentsPageByObjectIdResponse(id=2193430, encodeId=d7612193430bc, content=在线求BIOMED PHARMACOTHER 官网邮箱,谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2e651733589, createdName=今夜有雨, createdTime=Fri Mar 15 16:36:23 CST 2024, time=2024-03-15, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2189719, encodeId=4dde2189e1973, content=写邮件申请延长修稿时间是直接回复系统发送的邮件还是在官网系统上发送邮件啊?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18898386622, createdName=ms7000000856963905, createdTime=Tue Feb 27 18:39:38 CST 2024, time=2024-02-27, status=1, ipAttribution=江苏省)]
    2024-03-11 ms3000000361924578 来自北京

    记录一下,2月22日投稿,1600+,还是submitted to journal

    2

    展开2条回复
  6. [GetPortalCommentsPageByObjectIdResponse(id=2185142, encodeId=63162185142c0, content=多久有人愿意审稿呀。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22b46401167, createdName=ms8000001441772842, createdTime=Wed Jan 31 23:23:06 CST 2024, time=2024-01-31, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2189500, encodeId=7ef62189500b2, content=偏重的研究方向:肿瘤<br>经验分享:年前投稿的,昨天送审,1000+号, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4019047506, createdName=ms2000001254072347, createdTime=Mon Feb 26 19:11:05 CST 2024, time=2024-02-26, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2192087, encodeId=2e7d219208ead, content=记录一下,2.16投稿的,1300+,今天还是Submitted to journal, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=aa0b5490731, createdName=chy, createdTime=Fri Mar 08 14:54:38 CST 2024, time=2024-03-08, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2175017, encodeId=05c721e5017e2, content=审稿速度:1.0 | 投稿命中率:75.0<br>偏重的研究方向:肿瘤;综述<br>经验分享:66**号,第二次投稿(8月初第一次没找到审稿人,一个月拒了,说欢迎修改题目和关键词后重投),第二次投稿邀请了25个人,终于找到了一个审稿人愿意审稿,小修了2次(相当于这个审稿人审了3次文章),每次都是审10天左右,然后等编辑5天左右做决定,也就是一次修稿周期就得20天,今天终于接收了。9月18号投的稿。 送审之后修回的概率很大,对大而不精的综述特别友好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/20/36e4b1345247d92b63b923885e50e463.jpg, createdBy=921d5250503, createdName=147ddcd3m55暂无昵称, createdTime=Fri Dec 15 01:05:53 CST 2023, time=2023-12-15, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2192558, encodeId=95eb21925583c, content=记录一下,2月22日投稿,1600+,还是submitted to journal, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2f7f5535320, createdName=ms3000000361924578, createdTime=Mon Mar 11 14:09:31 CST 2024, time=2024-03-11, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2185510, encodeId=c458218551089, content=偏重的研究方向:心血管<br>经验分享:2023年12月8 Submitted<br>2024年1月15 with editor<br>2024年1月30 Under Review<br>还要多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=98188622439, createdName=ms3000001775227501, createdTime=Fri Feb 02 15:09:20 CST 2024, time=2024-02-02, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2193046, encodeId=494b21930461d, content=偏重的研究方向:肿瘤;综述<br>经验分享:为啥找不到审稿人呢<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4019047506, createdName=ms2000001254072347, createdTime=Wed Mar 13 20:37:05 CST 2024, time=2024-03-13, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2194188, encodeId=3695219418871, content=好像最近没有中国人的论著文章发表, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0ea8286723, createdName=ms3000000851999119, createdTime=Tue Mar 19 23:26:22 CST 2024, time=2024-03-19, status=1, ipAttribution=弗吉尼亚), GetPortalCommentsPageByObjectIdResponse(id=2193430, encodeId=d7612193430bc, content=在线求BIOMED PHARMACOTHER 官网邮箱,谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2e651733589, createdName=今夜有雨, createdTime=Fri Mar 15 16:36:23 CST 2024, time=2024-03-15, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2189719, encodeId=4dde2189e1973, content=写邮件申请延长修稿时间是直接回复系统发送的邮件还是在官网系统上发送邮件啊?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18898386622, createdName=ms7000000856963905, createdTime=Tue Feb 27 18:39:38 CST 2024, time=2024-02-27, status=1, ipAttribution=江苏省)]
    2024-02-02 ms3000001775227501 来自福建省

    偏重的研究方向:心血管
    经验分享:2023年12月8 Submitted
    2024年1月15 with editor
    2024年1月30 Under Review
    还要多久啊

    1

    展开1条回复
  7. [GetPortalCommentsPageByObjectIdResponse(id=2185142, encodeId=63162185142c0, content=多久有人愿意审稿呀。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22b46401167, createdName=ms8000001441772842, createdTime=Wed Jan 31 23:23:06 CST 2024, time=2024-01-31, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2189500, encodeId=7ef62189500b2, content=偏重的研究方向:肿瘤<br>经验分享:年前投稿的,昨天送审,1000+号, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4019047506, createdName=ms2000001254072347, createdTime=Mon Feb 26 19:11:05 CST 2024, time=2024-02-26, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2192087, encodeId=2e7d219208ead, content=记录一下,2.16投稿的,1300+,今天还是Submitted to journal, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=aa0b5490731, createdName=chy, createdTime=Fri Mar 08 14:54:38 CST 2024, time=2024-03-08, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2175017, encodeId=05c721e5017e2, content=审稿速度:1.0 | 投稿命中率:75.0<br>偏重的研究方向:肿瘤;综述<br>经验分享:66**号,第二次投稿(8月初第一次没找到审稿人,一个月拒了,说欢迎修改题目和关键词后重投),第二次投稿邀请了25个人,终于找到了一个审稿人愿意审稿,小修了2次(相当于这个审稿人审了3次文章),每次都是审10天左右,然后等编辑5天左右做决定,也就是一次修稿周期就得20天,今天终于接收了。9月18号投的稿。 送审之后修回的概率很大,对大而不精的综述特别友好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/20/36e4b1345247d92b63b923885e50e463.jpg, createdBy=921d5250503, createdName=147ddcd3m55暂无昵称, createdTime=Fri Dec 15 01:05:53 CST 2023, time=2023-12-15, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2192558, encodeId=95eb21925583c, content=记录一下,2月22日投稿,1600+,还是submitted to journal, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2f7f5535320, createdName=ms3000000361924578, createdTime=Mon Mar 11 14:09:31 CST 2024, time=2024-03-11, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2185510, encodeId=c458218551089, content=偏重的研究方向:心血管<br>经验分享:2023年12月8 Submitted<br>2024年1月15 with editor<br>2024年1月30 Under Review<br>还要多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=98188622439, createdName=ms3000001775227501, createdTime=Fri Feb 02 15:09:20 CST 2024, time=2024-02-02, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2193046, encodeId=494b21930461d, content=偏重的研究方向:肿瘤;综述<br>经验分享:为啥找不到审稿人呢<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4019047506, createdName=ms2000001254072347, createdTime=Wed Mar 13 20:37:05 CST 2024, time=2024-03-13, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2194188, encodeId=3695219418871, content=好像最近没有中国人的论著文章发表, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0ea8286723, createdName=ms3000000851999119, createdTime=Tue Mar 19 23:26:22 CST 2024, time=2024-03-19, status=1, ipAttribution=弗吉尼亚), GetPortalCommentsPageByObjectIdResponse(id=2193430, encodeId=d7612193430bc, content=在线求BIOMED PHARMACOTHER 官网邮箱,谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2e651733589, createdName=今夜有雨, createdTime=Fri Mar 15 16:36:23 CST 2024, time=2024-03-15, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2189719, encodeId=4dde2189e1973, content=写邮件申请延长修稿时间是直接回复系统发送的邮件还是在官网系统上发送邮件啊?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18898386622, createdName=ms7000000856963905, createdTime=Tue Feb 27 18:39:38 CST 2024, time=2024-02-27, status=1, ipAttribution=江苏省)]
    2024-03-13 ms2000001254072347 来自四川省

    偏重的研究方向:肿瘤;综述
    经验分享:为啥找不到审稿人呢

    2

    展开2条回复
  8. [GetPortalCommentsPageByObjectIdResponse(id=2185142, encodeId=63162185142c0, content=多久有人愿意审稿呀。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22b46401167, createdName=ms8000001441772842, createdTime=Wed Jan 31 23:23:06 CST 2024, time=2024-01-31, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2189500, encodeId=7ef62189500b2, content=偏重的研究方向:肿瘤<br>经验分享:年前投稿的,昨天送审,1000+号, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4019047506, createdName=ms2000001254072347, createdTime=Mon Feb 26 19:11:05 CST 2024, time=2024-02-26, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2192087, encodeId=2e7d219208ead, content=记录一下,2.16投稿的,1300+,今天还是Submitted to journal, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=aa0b5490731, createdName=chy, createdTime=Fri Mar 08 14:54:38 CST 2024, time=2024-03-08, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2175017, encodeId=05c721e5017e2, content=审稿速度:1.0 | 投稿命中率:75.0<br>偏重的研究方向:肿瘤;综述<br>经验分享:66**号,第二次投稿(8月初第一次没找到审稿人,一个月拒了,说欢迎修改题目和关键词后重投),第二次投稿邀请了25个人,终于找到了一个审稿人愿意审稿,小修了2次(相当于这个审稿人审了3次文章),每次都是审10天左右,然后等编辑5天左右做决定,也就是一次修稿周期就得20天,今天终于接收了。9月18号投的稿。 送审之后修回的概率很大,对大而不精的综述特别友好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/20/36e4b1345247d92b63b923885e50e463.jpg, createdBy=921d5250503, createdName=147ddcd3m55暂无昵称, createdTime=Fri Dec 15 01:05:53 CST 2023, time=2023-12-15, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2192558, encodeId=95eb21925583c, content=记录一下,2月22日投稿,1600+,还是submitted to journal, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2f7f5535320, createdName=ms3000000361924578, createdTime=Mon Mar 11 14:09:31 CST 2024, time=2024-03-11, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2185510, encodeId=c458218551089, content=偏重的研究方向:心血管<br>经验分享:2023年12月8 Submitted<br>2024年1月15 with editor<br>2024年1月30 Under Review<br>还要多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=98188622439, createdName=ms3000001775227501, createdTime=Fri Feb 02 15:09:20 CST 2024, time=2024-02-02, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2193046, encodeId=494b21930461d, content=偏重的研究方向:肿瘤;综述<br>经验分享:为啥找不到审稿人呢<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4019047506, createdName=ms2000001254072347, createdTime=Wed Mar 13 20:37:05 CST 2024, time=2024-03-13, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2194188, encodeId=3695219418871, content=好像最近没有中国人的论著文章发表, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0ea8286723, createdName=ms3000000851999119, createdTime=Tue Mar 19 23:26:22 CST 2024, time=2024-03-19, status=1, ipAttribution=弗吉尼亚), GetPortalCommentsPageByObjectIdResponse(id=2193430, encodeId=d7612193430bc, content=在线求BIOMED PHARMACOTHER 官网邮箱,谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2e651733589, createdName=今夜有雨, createdTime=Fri Mar 15 16:36:23 CST 2024, time=2024-03-15, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2189719, encodeId=4dde2189e1973, content=写邮件申请延长修稿时间是直接回复系统发送的邮件还是在官网系统上发送邮件啊?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18898386622, createdName=ms7000000856963905, createdTime=Tue Feb 27 18:39:38 CST 2024, time=2024-02-27, status=1, ipAttribution=江苏省)]
    2024-03-19 ms3000000851999119 来自弗吉尼亚

    好像最近没有中国人的论著文章发表

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=2185142, encodeId=63162185142c0, content=多久有人愿意审稿呀。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22b46401167, createdName=ms8000001441772842, createdTime=Wed Jan 31 23:23:06 CST 2024, time=2024-01-31, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2189500, encodeId=7ef62189500b2, content=偏重的研究方向:肿瘤<br>经验分享:年前投稿的,昨天送审,1000+号, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4019047506, createdName=ms2000001254072347, createdTime=Mon Feb 26 19:11:05 CST 2024, time=2024-02-26, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2192087, encodeId=2e7d219208ead, content=记录一下,2.16投稿的,1300+,今天还是Submitted to journal, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=aa0b5490731, createdName=chy, createdTime=Fri Mar 08 14:54:38 CST 2024, time=2024-03-08, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2175017, encodeId=05c721e5017e2, content=审稿速度:1.0 | 投稿命中率:75.0<br>偏重的研究方向:肿瘤;综述<br>经验分享:66**号,第二次投稿(8月初第一次没找到审稿人,一个月拒了,说欢迎修改题目和关键词后重投),第二次投稿邀请了25个人,终于找到了一个审稿人愿意审稿,小修了2次(相当于这个审稿人审了3次文章),每次都是审10天左右,然后等编辑5天左右做决定,也就是一次修稿周期就得20天,今天终于接收了。9月18号投的稿。 送审之后修回的概率很大,对大而不精的综述特别友好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/20/36e4b1345247d92b63b923885e50e463.jpg, createdBy=921d5250503, createdName=147ddcd3m55暂无昵称, createdTime=Fri Dec 15 01:05:53 CST 2023, time=2023-12-15, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2192558, encodeId=95eb21925583c, content=记录一下,2月22日投稿,1600+,还是submitted to journal, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2f7f5535320, createdName=ms3000000361924578, createdTime=Mon Mar 11 14:09:31 CST 2024, time=2024-03-11, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2185510, encodeId=c458218551089, content=偏重的研究方向:心血管<br>经验分享:2023年12月8 Submitted<br>2024年1月15 with editor<br>2024年1月30 Under Review<br>还要多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=98188622439, createdName=ms3000001775227501, createdTime=Fri Feb 02 15:09:20 CST 2024, time=2024-02-02, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2193046, encodeId=494b21930461d, content=偏重的研究方向:肿瘤;综述<br>经验分享:为啥找不到审稿人呢<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4019047506, createdName=ms2000001254072347, createdTime=Wed Mar 13 20:37:05 CST 2024, time=2024-03-13, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2194188, encodeId=3695219418871, content=好像最近没有中国人的论著文章发表, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0ea8286723, createdName=ms3000000851999119, createdTime=Tue Mar 19 23:26:22 CST 2024, time=2024-03-19, status=1, ipAttribution=弗吉尼亚), GetPortalCommentsPageByObjectIdResponse(id=2193430, encodeId=d7612193430bc, content=在线求BIOMED PHARMACOTHER 官网邮箱,谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2e651733589, createdName=今夜有雨, createdTime=Fri Mar 15 16:36:23 CST 2024, time=2024-03-15, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2189719, encodeId=4dde2189e1973, content=写邮件申请延长修稿时间是直接回复系统发送的邮件还是在官网系统上发送邮件啊?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18898386622, createdName=ms7000000856963905, createdTime=Tue Feb 27 18:39:38 CST 2024, time=2024-02-27, status=1, ipAttribution=江苏省)]
    2024-03-15 今夜有雨 来自河南省

    在线求BIOMED PHARMACOTHER 官网邮箱,谢谢

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=2185142, encodeId=63162185142c0, content=多久有人愿意审稿呀。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22b46401167, createdName=ms8000001441772842, createdTime=Wed Jan 31 23:23:06 CST 2024, time=2024-01-31, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2189500, encodeId=7ef62189500b2, content=偏重的研究方向:肿瘤<br>经验分享:年前投稿的,昨天送审,1000+号, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4019047506, createdName=ms2000001254072347, createdTime=Mon Feb 26 19:11:05 CST 2024, time=2024-02-26, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2192087, encodeId=2e7d219208ead, content=记录一下,2.16投稿的,1300+,今天还是Submitted to journal, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=aa0b5490731, createdName=chy, createdTime=Fri Mar 08 14:54:38 CST 2024, time=2024-03-08, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2175017, encodeId=05c721e5017e2, content=审稿速度:1.0 | 投稿命中率:75.0<br>偏重的研究方向:肿瘤;综述<br>经验分享:66**号,第二次投稿(8月初第一次没找到审稿人,一个月拒了,说欢迎修改题目和关键词后重投),第二次投稿邀请了25个人,终于找到了一个审稿人愿意审稿,小修了2次(相当于这个审稿人审了3次文章),每次都是审10天左右,然后等编辑5天左右做决定,也就是一次修稿周期就得20天,今天终于接收了。9月18号投的稿。 送审之后修回的概率很大,对大而不精的综述特别友好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/20/36e4b1345247d92b63b923885e50e463.jpg, createdBy=921d5250503, createdName=147ddcd3m55暂无昵称, createdTime=Fri Dec 15 01:05:53 CST 2023, time=2023-12-15, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2192558, encodeId=95eb21925583c, content=记录一下,2月22日投稿,1600+,还是submitted to journal, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2f7f5535320, createdName=ms3000000361924578, createdTime=Mon Mar 11 14:09:31 CST 2024, time=2024-03-11, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2185510, encodeId=c458218551089, content=偏重的研究方向:心血管<br>经验分享:2023年12月8 Submitted<br>2024年1月15 with editor<br>2024年1月30 Under Review<br>还要多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=98188622439, createdName=ms3000001775227501, createdTime=Fri Feb 02 15:09:20 CST 2024, time=2024-02-02, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2193046, encodeId=494b21930461d, content=偏重的研究方向:肿瘤;综述<br>经验分享:为啥找不到审稿人呢<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4019047506, createdName=ms2000001254072347, createdTime=Wed Mar 13 20:37:05 CST 2024, time=2024-03-13, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2194188, encodeId=3695219418871, content=好像最近没有中国人的论著文章发表, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0ea8286723, createdName=ms3000000851999119, createdTime=Tue Mar 19 23:26:22 CST 2024, time=2024-03-19, status=1, ipAttribution=弗吉尼亚), GetPortalCommentsPageByObjectIdResponse(id=2193430, encodeId=d7612193430bc, content=在线求BIOMED PHARMACOTHER 官网邮箱,谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2e651733589, createdName=今夜有雨, createdTime=Fri Mar 15 16:36:23 CST 2024, time=2024-03-15, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2189719, encodeId=4dde2189e1973, content=写邮件申请延长修稿时间是直接回复系统发送的邮件还是在官网系统上发送邮件啊?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18898386622, createdName=ms7000000856963905, createdTime=Tue Feb 27 18:39:38 CST 2024, time=2024-02-27, status=1, ipAttribution=江苏省)]
    2024-02-27 ms7000000856963905 来自江苏省

    写邮件申请延长修稿时间是直接回复系统发送的邮件还是在官网系统上发送邮件啊?

    1

    展开1条回复
共500条页码: 1/50页10条/页
分享您的投稿经验,提升MI经验值,获取更多积分